Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

Published Date: 28 Mar 2026

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

Read Full News

Latest News

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

Todays Updates

All-Oral Treatment Combo for AML Earns FDA Nod

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Todays Updates

All-Oral Treatment Combo for AML Earns FDA Nod

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Latest News

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

News All Time

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Is Vitamin D a Key to Better Breast Cancer Survival?

A prospective study links sufficient vitamin D levels at the time of breast cancer diagnosis to improved overall survival.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

3.

Do Anatomy Atlases Reflect Social Inequalities?

4.

Modified personalized cancer vaccine generates powerful immune response

5.

Enthusiasm for Transplant-Free Strategies for Low-Risk Relapsed Hodgkin Lymphoma

1.

CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target

2.

Uncovering Dyscrasia: A Comprehensive Guide to Diagnosis and Treatment

3.

Understanding SVR Normal Range: A Guide to Achieving Optimal Health

4.

Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies

5.

AI in Cancer Diagnostics and Imaging Interpretation

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Should We Use DARA Up Front As First-Line Therapy in MM?

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

3.

Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care

4.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion

5.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

Latest News

Low PSA May Not Fully Predict Survival in Prostate Cancer

Only 1 in 4 Eligible Adults Receive Lung Screening

FDA Warns of Secondary Blood Cancer Risk With Tazverik

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

When Healthcare Chatbots Fall Short of Human Connection

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

Todays Updates

All-Oral Treatment Combo for AML Earns FDA Nod

Todays Updates

All-Oral Treatment Combo for AML Earns FDA Nod

Latest News

News All Time

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Can Exercise Extend Survival After Breast Cancer?

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Can Alternating Venetoclax Regimens Improve AML Outcomes?

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Which Risk Model Better Identifies High-Risk Smoldering MM?

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

Dasatinib Fails to Improve Outcomes in CBF-AML

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

Measurable Residual Disease Predicts Real-World AML Relapse

Can Oncotype Predict Recurrence Risk in Older BC Patients?

Is Vitamin D a Key to Better Breast Cancer Survival?

Recommended News For You

A new therapeutic approach could help tackle radiation resistance in childhood brain tumors

Health researchers discuss Medicaid cancer screening trends, best practices

Do Anatomy Atlases Reflect Social Inequalities?